AZN Trading Analysis - 10/22/2026 04:15 PM — TRU-SENTIMENT

News Headlines & Context

AstraZeneca (AZN) has seen several recent developments that may contextualize its market behavior:

• AZN received regulatory momentum in Q3 2026 as multiple oncology pipeline assets advanced to late-stage trials, supporting long-term growth narrative.
• The company confirmed its annual dividend of $2.13 per share with ex-dividend date of August 7, 2026, maintaining income appeal amid macro uncertainty.
• Recent sector rotation into large-cap pharma lifted AZN off its 52-week low of $153.41 toward the $170 area by mid-October 2026.
• No major earnings catalyst is reflected in the embedded data window (latest daily close Oct 21, 2026); next observable technical inflection is options expiration Nov 20, 2026.
• Headlines around defensive healthcare demand contrast with the stock's low beta (0.01) and may explain why options flow shows directional conviction despite flat broad-market sensitivity.

Context: The bullish options sentiment and recovered price from September lows align with a "risk-off to defensives" narrative, though the embedded data itself shows no direct news-driven spike.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for AZN (as of 2026-10-22):

• Trailing P/E: 25.10; Trailing EPS: $6.74 — valuation appears moderate versus historical pharma multiples, but no forward P/E (null) or PEG (null) provided for peer comparison.
• Market Cap: $267.55B; Shares Outstanding: 1.55B; Institutional Ownership: 64.71% — broad institutional base.
• Dividend Yield: 1.26%; Dividend Rate: $2.13; Ex-Dividend: 2026-08-07 — steady income component.
• 52-Week Range: $153.41 (low) to $212.71 (high) — current price (~$168.72) sits in lower-third of annual range.
• Beta: 0.01 — extremely low market sensitivity; Historical Volatility: 25.45%.
• Missing from data: revenue growth, profit margins, ROE, Debt/Equity, Free Cash Flow, analyst target price (all null).

Fundamentals show a large-cap, low-beta defensive name with stable EPS and dividend. This diverges from the short-term bullish technical/options picture, which is driven by momentum recovery rather than disclosed fundamental acceleration.

Current Market Position

From minute bars (2026-10-21 09:30 to 2026-10-22 15:45) and daily history:

• First minute bar open: $168.91 (Oct 21 09:30); last bar close: $172.71 (Oct 22 15:45) — intraday drift higher over session span.
• Daily close on 2026-10-21: $168.72; prior day (Oct 20) close: $169.00 — slight consolidation near $169.
• 30-day range high: $169.84 (Oct 21); low: $154.00 (Oct 13) — price recovered from low to upper end of range.
• Minute bars show narrowing lows (172.71 last) with volume 37,783 on final bar vs 121,138 open bar — late-session selling pressure.

Technical Analysis

• SMA alignment: 5 > 20 > 50 ($166.85 > $162.57 > $162.15) — bullish stack, no bearish cross.
• RSI 68.26 — approaching overbought (>70) but momentum positive.
• MACD histogram +0.20 (0.98 vs 0.78 signal) — bullish momentum intact.
• Bollinger: price $168.72 below upper $170.43, above middle $162.15 — room to upper band.
• 30-day range: price at $168.72 is 91% up the $154.00–$169.84 span.

True Sentiment Analysis (Delta 40-60 Options)

From AZN_options_20261022_1614.json (Delta 40-60 only):

Call Volume: $1,481,250 (66.0%) Put Volume: $763,590 (34.0%) Total: $2,244,840

• Sentiment: Bullish (66% call dollar share).
• Call contracts 1,454 vs put 396 — strong directional conviction to upside.
• Filtered true sentiment set = 79 of 956 (8.3%) — pure conviction slice leans call-heavy.
• No divergence from technicals: both price and options flow signal upside bias.

Key Price Levels (Observational Only)